VYGR.NASDAQVoyager Therapeutics, INC

Form 4: Voyager Therapeutics CEO Alfred Sandrock Sells Shares to Cover Tax Obligations

Sentiment:

SEC Form 4 Filing

📋All filings for Voyager Therapeutics, INC
🔒Login to Follow

Voyager Therapeutics CEO Alfred Sandrock sold 12,115 shares of common stock on April 2, 2024, to cover tax obligations related to vesting restricted stock units.

Summary

  • On April 2, 2024, Alfred Sandrock, the President and CEO of Voyager Therapeutics, sold 12,115 shares of Voyager Therapeutics (VYGR) common stock.
  • The sale was executed to cover tax withholding obligations associated with the vesting of restricted stock units on April 1, 2024.
  • The shares were sold at a weighted average price of $9.86, with individual transactions ranging from $9.71 to $10.02.
  • Following the transaction, Sandrock directly owns 322,839 shares of Voyager Therapeutics common stock.
  • The sale was conducted automatically according to a pre-arranged sales instruction letter and does not represent a discretionary trade.

Sentiment

Score: 5

Explanation: The document describes a routine transaction (selling shares to cover taxes) and doesn't contain information that would significantly sway investor sentiment positively or negatively.

Industry Context

Form 4 filings are a routine part of the US stock market, providing transparency into the transactions of company insiders. This filing indicates a sale of shares to cover tax obligations, which is a common practice.

Key Dates

DateDescription
04/01/2024Restricted stock units vested, triggering tax obligations.
04/02/2024Alfred Sandrock sold 12,115 shares of Voyager Therapeutics common stock.
04/03/2024Date of signature for the Form 4 filing.

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.